VivoSeq
Other

Hip Replacement Surgery

0

Pipeline Programs↗

1

Active Trials↗

7

Companies Involved↗

Hip Replacement Surgery is an early-stage landscape with 0 programs across 7 companies. The most active players are Bristol-Myers Squibb, Sanofi, Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalDaiichi Sankyo logo

Daiichi Sankyo

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalJohnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

19

clinical trials

Completed16 · 84%
Recruiting1 · 5%
Withdrawn1 · 5%
Terminated1 · 5%

Clinical Trials

Trial Activity

19 trials

Comparing the Safety and Effectiveness of Different Doses of Morphine Administered in Spinal Anethesia for Pain Relief After Hip Replacement Surgery
Recruiting·MMedical University of Silesia·Phase 4·NCT06878014·120 enrolled
Ultrasound Guided Fascia Iliaca Block for Pain Control After Elective Hip Replacement Surgery
Completed·UUniversity of Saskatchewan·N/A·NCT02108847·42 enrolled
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT00423319·5,407 enrolled
Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery
Completed·TTalphera, Inc·Phase 3·NCT01660763·419 enrolled
Impact of Deep Neuromuscular Blockade During Total Hip Replacement Surgery on Postoperative Recovery and Immune Function
Completed·RRadboud University Medical Center·Phase 4·NCT05562999·100 enrolled
The Immunomodulatory Effect of Sugammadex After Total Hip Replacement Surgery Under Neuraxial Anaesthesia: a Pilot Study
Completed·RRadboud University Medical Center·Phase 2·NCT05723406·20 enrolled
Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
Completed·DDebiopharm International SA·Phase 1·NCT02726438·17 enrolled
Dose Ranging Study in Elective Total Hip Replacement Surgery
Completed·Sanofi logoSanofi·Phase 2/3·NCT00338897·1,090 enrolled
Prevention of Ectopic Bone Related Pain and Disability After Hip Replacement Surgery With Peri-Operative Ibuprofen
Completed·TThe George Institute·Phase 4·NCT00145730·1,000 enrolled
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT00398216·903 enrolled
Effect of a Lateral Nerve of the Thigh Block on Postoperative Pain After Total Hip Replacement Surgery
Completed·—·Phase 4·NCT02289937·100 enrolled
Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT02170935·62 enrolled
Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 4·NCT01884337·557 enrolled
Tranexamic Acid Versus Placebo for the Reduction of Blood Loss in Total Hip Replacement Surgery
Completed·BBasque Health Service·Phase 3·NCT01199627·114 enrolled
Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
Completed·TThromboGenics·Phase 2·NCT01344954·632 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)